Open AccessThe effect of nintedanib versus mycophenolate mofetil in the Fra2 mouse model of systemic sclerosis-associated interstitial lung disease
Author(s) -
Lutz Wollin,
Thuong Trinh-Minh,
Yun Zhang,
Jörg H W Distler
Publication year - 2021
Publication title -
clinical and experimental rheumatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.184
H-Index - 95
eISSN - 1593-098X
pISSN - 0392-856X
DOI - 10.55563/clinexprheumatol/g5mej7
Subject(s) - nintedanib , medicine , interstitial lung disease , idiopathic pulmonary fibrosis , fibrosis , bosentan , pulmonary fibrosis , pulmonary hypertension , pathology , vital capacity , lung , diffusing capacity , endothelin receptor , lung function , receptor
Interstitial lung disease (ILD) is a key driver of mortality in patients with systemic sclerosis (SSc). A lack of approved treatments encompasses a high unmet medical need. Nintedanib has recently been approved for treatment in SSc-associated ILD (SSc-ILD) following SENSCIS®, a Phase III clinical trial showing that nintedanib slows the loss of pulmonary function in patients with SSc-ILD relative to placebo, as measured by annual rate of decline in forced vital capacity over 52 weeks. The aim of this study was to compare the activity of nintedanib and mycophenolate mofetil (MMF) in a transgenic Fra2 mouse model of SSc-ILD.